Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

Key Points

• Insider Joseph Lyssikatos sold 12,500 shares of Enliven Therapeutics at an average price of $22.08, resulting in a total transaction value of $276,000.
• The company's stock has a market capitalization of $1.21 billion and recent trading activity shows it reaching $20.49, reflecting a decrease of $0.70 during the session.
• Analysts have mixed opinions, with some rating the stock as a "Moderate Buy" while others like Weiss Ratings issued a "sell" recommendation.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 12,500 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $22.08, for a total transaction of $276,000.00. Following the transaction, the insider directly owned 915,188 shares in the company, valued at approximately $20,207,351.04. The trade was a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN traded down $0.70 during mid-day trading on Wednesday, reaching $20.49. The company's stock had a trading volume of 311,377 shares, compared to its average volume of 401,566. The stock has a 50-day moving average of $20.13 and a two-hundred day moving average of $19.63. The stock has a market capitalization of $1.21 billion, a P/E ratio of -10.25 and a beta of 0.85. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $29.78.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its position in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after acquiring an additional 3,490 shares during the period. Duquesne Family Office LLC acquired a new position in shares of Enliven Therapeutics during the second quarter valued at about $9,288,000. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after purchasing an additional 930 shares during the period. Bank of America Corp DE increased its position in shares of Enliven Therapeutics by 20.0% during the second quarter. Bank of America Corp DE now owns 24,508 shares of the company's stock valued at $492,000 after purchasing an additional 4,078 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Enliven Therapeutics by 150.4% in the second quarter. Ameriprise Financial Inc. now owns 59,244 shares of the company's stock valued at $1,188,000 after acquiring an additional 35,582 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.